Jayasooriya, Nishani;
Blackwell, Jonathan;
Saxena, Sonia;
Bottle, Alex;
Petersen, Irene;
Creese, Hanna;
Hotopf, Matthew;
... POP-IBD study group, .; + view all
(2022)
Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study.
Alimentary Pharmacology & Therapeutics
10.1111/apt.16820.
(In press).
Preview |
Text
Petersen_Antidepressant medication use in Inflammatory Bowel Disease_AOP.pdf - Published Version Download (688kB) | Preview |
Abstract
BACKGROUND: Despite high rates of depression and anxiety, little is known about the use of antidepressants amongst individuals diagnosed with inflammatory bowel disease (IBD). AIMS: To evaluate temporal trends in the use of antidepressants; rates of antidepressant initiation and adherence of antidepressant use to international guidelines amongst individuals with IBD. METHODS: This is a study of 14,525 incident IBD cases from 2004 to 2016 compared with 58,027 controls matched 1:4 for age and sex from the Clinical Practice Research Datalink. After excluding tricyclic antidepressants, we performed a Cox regression analysis to determine the risk associated with antidepressant use and logistic regression analysis to determine risk associated with antidepressant undertreatment. RESULTS: Antidepressant use amongst individuals with IBD increased by 51% during the 12-year study period, who were 34% more likely to initiate antidepressants in the year after IBD diagnosis compared with controls (aHR:1.34, 95% CI 1.21-1.49). In those with IBD starting antidepressants, 67% received treatment lasting less than the duration recommended in international guidelines, of which 34% were treated for 1 month or less. 18-24 year olds were twice as likely to discontinue treatment within 1 month compared with those aged 40-60 years (aHR:2.03, 95% CI 1.40-2.95). Socioeconomic deprivation was also associated with early treatment discontinuation (aHR:1.40, 95% CI 1.07-1.83). CONCLUSIONS: In the year following IBD diagnosis individuals are significantly more likely to start antidepressants compared with controls, but treatment duration fell short of recommendations in the majority. Better integration of services may benefit individuals with IBD and psychiatric comorbidity.
| Type: | Article |
|---|---|
| Title: | Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study. |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/apt.16820 |
| Publisher version: | https://doi.org/10.1111/apt.16820 |
| Language: | English |
| Additional information: | © 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Crohn’s disease, antidepressant medication, antidepressants, anxiety, clinical practice research datalink, depression, incidence, inflammatory bowel disease, ulcerative colitis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Primary Care and Population Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10145121 |
Archive Staff Only
 |
View Item |
